Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.80
Bid: 112.80
Ask: 113.20
Change: -0.20 (-0.18%)
Spread: 0.40 (0.355%)
Open: 110.80
High: 115.00
Low: 110.80
Prev. Close: 113.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

Mon, 27th Nov 2023 19:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Saietta Group PLC - Towcester, England-based designer, engineer and manufacturer of 'eDrive' solutions for electric vehicles - Proposes placing and subscription of new shares to raise a minimum GBP5.2 million, pricing each share at 17 pence each. This is alongside a broker option to Canaccord Genuity Ltd for an additional GBP1.0 million. The fundraising is being conducted in two tranches: around GBP1.7 million raised via the firm fundraising and a minimum of GBP4.7 million via a conditional fundraising. The fundraising is expected to satisfy the company's working capital requirements through to the end of March 2024, by which time the company is expecting to have announced a number of major commercial developments.

----------

Syncona Ltd - London-based investor in healthcare companies - Notes that its portfolio company Autolus Therapeutics PLC submits biologics licence application to US Food & Drug Administration for obecabtagene autoleucel for patients with relapsed/refractory adult B-Cell acute lymphoblastic leukaemia. Says submission is based on data from the Felix study. Says Autolus has also made "significant" progress in preparing its manufacturing footprint for the planned commercial launch of obe-cel, with its new 70,000 square foot commercial manufacturing facility, The Nucleus, which has an initial designed capacity of 2,000 batches per year. Pending approval from the Food & Drug Administration for the biologics licence application submission, the company expects to initiate its commercial launch of obe-cel in the US in 2024. It also expects to file a marketing authorisation application for obe-cel with the European Medicines Agency in the first half of 2024.

----------

Molten Ventures PLC - London-based venture capital firm - Completes GBP55.0 million placing and subscription of 20.4 million new shares priced at 270p each, representing around 13% of all shares. The retail offer remains open and is expected to close on Tuesday at 1500 GMT.

----------

Quadrise PLC - London-based residual oil technology company - Says all resolutions pass at annual general meeting, but notes resolution 3 only passed with 68% of shareholders voting in favour. Resolution 3 relates to re-appointing Non-Executive Director Dilip Shah, who is to retire by rotation. The company says on this: "The board is committed to continuing our engagement with shareholders to understand the views of those who voted against resolution 3 and will consult with them over the next few months to listen carefully to feedback and determine any next steps."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
7 Aug 2020 08:17

Syncona portfolio company Freeline prices US IPO

(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.

Read more
3 Aug 2020 22:16

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

Read more
20 Jul 2020 08:44

Syncona Investee Freeline Therapeutics Files For Possible US Listing

Syncona Investee Freeline Therapeutics Files For Possible US Listing

Read more
20 Jul 2020 07:22

Syncona's Freeline files IPO registration document

(Sharecast News) - Healthcare investor Syncona said its portfolio company Freeline Therapeutics has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering (IPO).

Read more
13 Jul 2020 18:36

Syncona's Investee Freeline Publishes Further Data For FLT180a

Syncona's Investee Freeline Publishes Further Data For FLT180a

Read more
30 Jun 2020 10:33

Syncona Investee Freeline Raises USD120 Million And Mulls US Listing

Syncona Investee Freeline Raises USD120 Million And Mulls US Listing

Read more
30 Jun 2020 08:26

Syncona revalues holding in Freeline after expanded series C

(Sharecast News) - Healthcare investment and development company Syncona announced on Tuesday that Freeline Therapeutics - a biotechnology company focussed on developing curative gene therapies for chronic systemic diseases - has raised a further $80m (£65.09m) from specialist global institutional investors in an expanded series C round.

Read more
18 Jun 2020 16:40

DIRECTOR DEALINGS: Syncona Non-Exec Reverberi Buys GBP50,000 In Shares

DIRECTOR DEALINGS: Syncona Non-Exec Reverberi Buys GBP50,000 In Shares

Read more
15 Jun 2020 09:19

Former Bayer Healthcare Chief Medical Officer Malik Joins Syncona

Former Bayer Healthcare Chief Medical Officer Malik Joins Syncona

Read more
11 Jun 2020 09:26

Syncona Annual Assets Take Hit From Autolus Value But Likes Portfolio

Syncona Annual Assets Take Hit From Autolus Value But Likes Portfolio

Read more
11 Jun 2020 08:32

Syncona asset values fall after Autolus shares plunge

(Sharecast News) - Syncona reported a 13% fall in net asset value as the value of its life sciences division dropped by a quarter in its most recent financial year.

Read more
4 Jun 2020 18:21

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
29 May 2020 09:07

Syncona Investee Achilles Therapeutics Starts Melanoma Therapy Trial

Syncona Investee Achilles Therapeutics Starts Melanoma Therapy Trial

Read more
29 May 2020 08:12

Syncona portfolio firm Achilles doses first patient in T cell therapy trial

(Sharecast News) - Syncona announced on Friday that its portfolio company, Achilles Therapeutics, has dosed the first patient in a phase 1 and 2 clinical study of its clonal neoantigen T cell (cNeT) therapy, in patients with recurrent or metastatic malignant melanoma.

Read more
23 Apr 2020 11:01

Syncona Makes USD51 Million Investment Into SwanBio Therapeutics

Syncona Makes USD51 Million Investment Into SwanBio Therapeutics

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.